Cover Image
市場調查報告書

流感治療藥市場(產品 - Zanamivir,Oseltamivir,Peramivir,Amantadine,Rimantadine,Inosine,Laninamivir Octanoate;流通管道) - 全球產業分析,規模,佔有率,成長,趨勢及預測:2017年∼2025年

Influenza Medication Market (Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Laninamivir Octanoate; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 603244
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
流感治療藥市場(產品 - Zanamivir,Oseltamivir,Peramivir,Amantadine,Rimantadine,Inosine,Laninamivir Octanoate;流通管道) - 全球產業分析,規模,佔有率,成長,趨勢及預測:2017年∼2025年 Influenza Medication Market (Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Laninamivir Octanoate; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025
出版日期: 2018年01月15日 內容資訊: 英文 159 Pages
簡介

依各產品類型,流感治療藥市場分類為,Zanamivir、Oseltamivir、Peramivir、Amantadine、Rimantadine、Inosine以及其他(Laninamivir Octanoate等)。各市場區隔,按照全球流感治療藥市場需求的增加和技術進步等,市場相關要素大範圍分析。再加上估計市場規模時,考慮與前一年同期比較的成長率。各市場區隔的市場規模及預測,從2015年到2025年的期間提供。還有從2017年到2025年的預測期間的各市場區隔的考慮複合年率成長率(年複合成長率%) 2016年基準年。

本報告提供全球流感治療藥市場相關分析,產品概要和最新的市場形勢,整體市場規模趨勢預測 、各產品、各地區的詳細趨勢,主要企業的簡介、市場佔有率等調查。

目錄

第1章 簡介

  • 報告範圍和市場區隔
  • 調查的重點

第2章 前提和調查方法

  • 前提
  • 調查方法

第3章 摘要整理

  • 全球流感治療藥市場概述

第4章 市場概要

  • 產品概要
  • 主要產業活動
  • 全球流感治療藥市場規模(百萬US美元)、預測:2015-2025年
  • 市場機會藍圖
  • 波特的五力分析
  • 價值鏈分析
  • 全球流感治療藥市場預測
  • 主要收益分析
  • 市場滲透策略

第5章 市場動態

  • 成長要素及阻礙因素的概述分析
  • 成長要素
    • 流感的流行及發病率的增加
    • 重視研究帶來開發新進步的治療和藥
    • 醫生與採用醫藥品集造成的快速核准
    • 新型流感的發生
    • 為了治療和預防流感
    • 對醫療保健的政府支出增加
  • 阻礙因素
    • 高開發成本
    • 抗病毒療法的副作用
  • 市場機會
    • 透過夥伴關係的產品開發
    • 有效性高副作用少的替代機制

第6章 全球流感治療藥市場分析:各產品

  • 簡介
  • 主要的觀察
  • 市場佔有率分析(以金額為準)
  • 市場預測
    • Zanamivir
    • Oseltamivir
    • Peramivir
    • amantadin
    • rimantadin
    • Inosine
    • 其他(Laninamivir Octanoate等)
  • 市場分析
  • 市場魅力分析

第7章 全球流感治療藥市場分析:各銷售管道

  • 簡介
  • 主要的觀察
  • 市場佔有率分析(以金額為準)
  • 市場預測
    • 醫院
    • 診療所
    • 藥局
    • 其他
  • 市場分析
  • 市場魅力分析

第8章 全球流感治療藥市場分析:各地區

  • 各國全球市場方案
  • 市場佔有率分析(以金額為準)
  • 市場預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東、非洲

第14章 競爭情形

  • 競爭矩陣
  • 企業概要
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH (Novartis AG)
    • Sun Pharmaceutical Industries Ltd.
    • Mylan, Inc.
    • GlaxoSmithKline plc
    • Daiichi Sankyo Company
    • Natco Pharma
目錄

Title:
Influenza Medication Market (Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Laninamivir Octanoate; Distribution Channel - Hospitals, Clinics, and Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025.

Global Influenza Medication Market: Overview

This report on Influenza Medication Market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of Influenza Medication Market products such as Zanamivir, Oseltamivir, Peramivir, and others as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the Global Influenza Medication Market with respect to the leading market segments based on products segment, distribution channels, and geographies.

Global Influenza Medication Market: Key Segments

Based on the product type, the Influenza Medication Market has been segmented into: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine and Others (laninamivir octanoate, etc.). Each of the market segments have been extensively analyzed based on the market related factors such as increasing demand of Influenza Medication Market products worldwide, and technological advancement. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Influenza Medication Market: Scope of the Study

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Influenza Medication Market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global influenza medication market.

Global Influenza Medication Market: Regional Outlook

Geographically, influenza medication market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides with market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, Porter's five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Global Influenza Medication Market.

Companies Mentioned in Report

The key findings section included in the report would assist existing market players in expanding their market shares, and new companies in establishing their presence in the Global Influenza Medication Market. The report also profiles key players operating in the Influenza Medication Market which are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd. and Mylan, Inc..

The global influenza medication market is segmented as follows:

Global Influenza Medication Market, by Product

  • Zanamivir
  • Oseltamivir
  • Peramivir
  • Amantadine
  • Rimantadine
  • Inosine
  • Other (Laninamivir Octanoate, etc.)

Global Influenza Medication Market, by Distribution channel

  • Hospitals
  • Clinics
  • Pharmacies
  • Others

Global Influenza Medication Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Poland
    • Rest of the Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Influenza Medication Market Snapshot

4. Market Overview

  • 4.1. Product Overview
  • 4.2. Key Industry Events
  • 4.3. Global Influenza Medication Market Size (US$ Mn) Forecast, 2015-2025
  • 4.4. Market Opportunity Map
  • 4.5. Porter's Five Forces Analysis
  • 4.6. Value Chain Analysis
  • 4.7. Global Influenza Medication Market Outlook
  • 4.8. Major Revenue Pockets Analysis
  • 4.9. Market Penetration Strategies

5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Increase in prevalence and incidence of influenza
    • 5.2.2. Strong R&D focus resulting in new and advanced treatments and drugs
    • 5.2.3. Fast acceptance by physicians and drug formularies
    • 5.2.4. Outbreak of pandemic influenza
    • 5.2.5. for treatment and prevention of influenza
    • 5.2.6. Increasing government expenditure on health care
  • 5.3. Restraints
    • 5.3.1. High cost of drug development
    • 5.3.2. Side effects of antiviral therapy
  • 5.4. Opportunities
    • 5.4.1. Product development through partnerships
    • 5.4.2. Alternative mechanisms that might have higher efficacy and fewer side effects

6. Global Influenza Medication Market Analysis, by Product

  • 6.1. Introduction
  • 6.2. Key Findings
  • 6.3. Global Influenza Medication Market Value Share Analysis, by Product
  • 6.4. Global Influenza Medication Market Forecast, by Product
    • 6.4.1. Zanamivir
    • 6.4.2. Oseltamivir
    • 6.4.3. Peramivir
    • 6.4.4. Amantadine
    • 6.4.5. Rimantadine
    • 6.4.6. Inosine
    • 6.4.7. Other (Laninamivir Octanoate, etc.)
  • 6.5. Global Influenza Medication Market Analysis, by Product
  • 6.6. Global Influenza Medication Market Attractiveness Analysis, by Product

7. Global Influenza Medication Market Analysis, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Key Findings
  • 7.3. Global Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 7.4. Global Influenza Medication Market Forecast, by Distribution Channel
    • 7.4.1. Hospitals
    • 7.4.2. Clinics
    • 7.4.3. Pharmacies
    • 7.4.4. Others
  • 7.5. Global Influenza Medication Market Analysis, by Distribution Channel
  • 7.6. Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel

8. Global Influenza Medication Market Analysis, by Region

  • 8.1. Global Market Scenario by Country
  • 8.2. Global Influenza Medication Market Value Share Analysis, by Region
  • 8.3. Global Influenza Medication Market Forecast, by Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4. Global Influenza Medication Market Attractiveness Analysis, by Region

9. North America Influenza Medication Market Analysis

  • 9.1. Key Findings
  • 9.2. North America Influenza Medication Market Overview
  • 9.3. North America Influenza Medication Market Value Share Analysis, by Country
  • 9.4. North America Influenza Medication Market Forecast, by Country
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Influenza Medication Market Value Share Analysis, by Product
  • 9.6. North America Influenza Medication Market Value Share Analysis, by Product
  • 9.7. North America Influenza Medication Market Forecast, by Product
  • 9.8. North America Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 9.9. North America Influenza Medication Market Forecast, by Distribution Channel
  • 9.10. North America Influenza Medication Market Attractiveness Analysis
  • 9.11. Key Trends

10. Europe Influenza Medication Market Analysis

  • 10.1. Key Findings
  • 10.2. Europe Influenza Medication Market Overview
  • 10.3. Europe Influenza Medication Market Value Share Analysis, by Country
  • 10.4. Europe Influenza Medication Market Forecast, by Country
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Poland
    • 10.4.7. Rest of the Europe
  • 10.5. Europe Influenza Medication Market Value Share Analysis, by Product
  • 10.6. Europe Influenza Medication Market Value Share Analysis, by Product
  • 10.7. Europe Influenza Medication Market Forecast, by Product
  • 10.8. Europe Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 10.9. Europe Influenza Medication Market Forecast, by Distribution Channel
  • 10.10. Europe Influenza Medication Market Attractiveness Analysis
  • 10.11. Key Trends

11. Asia Pacific Influenza Medication Market Analysis

  • 11.1. Key Findings
  • 11.2. Asia Pacific Influenza Medication Market Overview
  • 11.3. Asia Pacific Influenza Medication Market Value Share Analysis, by Country
  • 11.4. Asia Pacific Influenza Medication Market Forecast, by Country
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. South Korea
    • 11.4.6. Rest of Asia Pacific
  • 11.5. Asia Pacific Influenza Medication Market Value Share Analysis, by Product
  • 11.6. Asia Pacific Influenza Medication Market Value Share Analysis, by Product
  • 11.7. Asia Pacific Influenza Medication Market Forecast, by Product
  • 11.8. Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 11.9. Asia Pacific Influenza Medication Market Forecast, by Distribution Channel
  • 11.10. Asia Pacific Influenza Medication Market Attractiveness Analysis
  • 11.11. Key Trends

12. Latin America Influenza Medication Market Analysis

  • 12.1. Key Findings
  • 12.2. Latin America Influenza Medication Market Overview
  • 12.3. Latin America Influenza Medication Market Value Share Analysis, by Country
  • 12.4. Latin America Influenza Medication Market Forecast, by Country
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Influenza Medication Market Value Share Analysis, by Product
  • 12.6. Latin America Influenza Medication Market Value Share Analysis, by Product
  • 12.7. Latin America Influenza Medication Market Forecast, by Product
  • 12.8. Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 12.9. Latin America Influenza Medication Market Forecast, by Distribution Channel
  • 12.10. Rest of World Influenza Medication Market Attractiveness Analysis
  • 12.11. Key Trends

13. Middle East and Africa Influenza Medication Market Analysis

  • 13.1. Key Findings
  • 13.2. Middle East and Africa Influenza Medication Market Overview
  • 13.3. Middle East and Africa Influenza Medication Market Value Share Analysis, by Country
  • 13.4. Middle East and Africa Influenza Medication Market Forecast, by Country
    • 13.4.1. South Africa
    • 13.4.2. Saudi Arabia
    • 13.4.3. UAE
    • 13.4.4. Rest of Middle East & Africa
  • 13.5. Middle East and Africa Influenza Medication Market Value Share Analysis, by Product
  • 13.6. Middle East and Africa Influenza Medication Market Value Share Analysis, by Product
  • 13.7. Middle East and Africa Influenza Medication Market Forecast, by Product
  • 13.8. Middle East and Africa Influenza Medication Market Value Share Analysis, by Distribution Channel
  • 13.9. Middle East and Africa Influenza Medication Market Forecast, by Distribution Channel
  • 13.10. Middle East and Africa Influenza Medication Market Attractiveness Analysis
  • 13.11. Key Trends

14. Competition Landscape

  • 14.1. Competition Matrix
  • 14.2. Company Profiles
    • 14.2.1. F. Hoffmann-La Roche Ltd.
      • 14.2.1.1. Company Details
      • 14.2.1.2. Business Overview
      • 14.2.1.3. Financial Overview
      • 14.2.1.4. Strategic Overview
      • 14.2.1.5. SWOT Analysis
    • 14.2.2. Teva Pharmaceutical Industries Ltd.
      • 14.2.2.1. Company Details
      • 14.2.2.2. Business Overview
      • 14.2.2.3. Financial Overview
      • 14.2.2.4. Strategic Overview
      • 14.2.2.5. SWOT Analysis
    • 14.2.3. Sandoz International GmbH (Novartis AG)
      • 14.2.3.1. Company Details
      • 14.2.3.2. Business Overview
      • 14.2.3.3. Financial Overview
      • 14.2.3.4. Strategic Overview
      • 14.2.3.5. SWOT Analysis
    • 14.2.4. Sun Pharmaceutical Industries Ltd.
      • 14.2.4.1. Company Details
      • 14.2.4.2. Business Overview
      • 14.2.4.3. Financial Overview
      • 14.2.4.4. Strategic Overview
      • 14.2.4.5. SWOT Analysis
    • 14.2.5. Mylan, Inc.
      • 14.2.5.1. Company Details
      • 14.2.5.2. Business Overview
      • 14.2.5.3. Financial Overview
      • 14.2.5.4. Strategic Overview
      • 14.2.5.5. SWOT Analysis
    • 14.2.6. GlaxoSmithKline plc
      • 14.2.6.1. Company Details
      • 14.2.6.2. Business Overview
      • 14.2.6.3. Financial Overview
      • 14.2.6.4. Strategic Overview
      • 14.2.6.5. SWOT Analysis
    • 14.2.7. Daiichi Sankyo Company
      • 14.2.7.1. Company Details
      • 14.2.7.2. Business Overview
      • 14.2.7.3. Financial Overview
      • 14.2.7.4. Strategic Overview
      • 14.2.7.5. SWOT Analysis
    • 14.2.8. Natco Pharma
      • 14.2.8.1. Company Details
      • 14.2.8.2. Business Overview
      • 14.2.8.3. Financial Overview
      • 14.2.8.4. Strategic Overview
      • 14.2.8.5. SWOT Analysis

List of Tables

  • Table 01: Global Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 02: Global Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 03: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Region, 2015-2025
  • Table 04: North America Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 05: North America Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 06: North America Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 07: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 08: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 09: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 10: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • Table 11: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 12: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channels, 2015-2025
  • Table 13: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 14: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 15: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 16: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 17: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015-2025
  • Table 18: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Influenza Medications Market Snapshot
  • Figure 02: Global Influenza Medication Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 04: Market Value Share, by Distribution Channels (2016)
  • Figure 03: Market Value Share, by Product (2016)
  • Figure 05: Market Value Share, by Region (2016)
  • Figure 06: Illustration of the Pharmaceutical Price Build-up
  • Figure 07: Global Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 08: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Zanamivir, 2015-2025
  • Figure 09: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Oseltamivir, 2015-2025
  • Figure 10: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Peramivir, 2015-2025
  • Figure 11: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Amantadine, 2015-2025
  • Figure 12: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Rimantadine, 2015-2025
  • Figure 13: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Inosine, 2015-2025
  • Figure 14: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Other (Laninamivir Octanoate, etc.), 2015-2025
  • Figure 15: Global Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 16: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 17: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Hospitals, 2015-2025
  • Figure 18: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Clinics, 2015-2025
  • Figure 19: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Pharmacies, 2015-2025
  • Figure 20: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2015-2025
  • Figure 21: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 22: Global Influenza Medication Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 23: Global Influenza Medication Market Attractiveness Analysis, by Region, 2017-2025
  • Figure 24: North America Influenza Medication Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Figure 25: North America Influenza Medication Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 26: North America Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 27: North America Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 28: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 29: North America Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 30: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 31: Europe Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 32: Europe Influenza Medication Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 33: Europe Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 34: Europe Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 35: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 36: Europe Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 37: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 38: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 39: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 40: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • Figure 41: Asia Pacific Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 42: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 43: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 44: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 45: Latin America Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Figure 46: Latin America Influenza Medication Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 47: Latin America Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 48: Latin America Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 49: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 50: Latin America Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 51: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 52: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Figure 53: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 54: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 55: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 56: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 57: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product, 2015-2025
  • Figure 58: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015-2025
  • Figure 59: Global Influenza Medication Market Share Analysis, by Company, 2016 (Estimated)
  • Figure 60: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016rv
  • Figure 61: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 62: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region (Pharmaceutical Segment), 2016
  • Figure 63: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (Overall Company Level), 2016
  • Figure 64: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 65: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) - Company Level or Segment Level, 2015-2016
  • Figure 66: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2016
  • Figure 67: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales (Overall Company Level), 2016
  • Figure 68: Sandoz International GmbH (Novartis AG) Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 69: Sandoz International GmbH (Novartis AG) R&D Intensity and Sales & Marketing Intensity (%) - Company Level or Segment Level, 2013-2016
  • Figure 70: Sandoz International GmbH (Novartis AG) Breakdown of Net Sales, by Region, 2016
  • Figure 71: Sandoz International GmbH (Novartis AG) Breakdown of Net Sales (Overall Company Level), 2016
  • Figure 72: Sun Pharmaceutical Industries Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 73: Sun Pharmaceutical Industries Ltd. R&D Intensity and Sales and Marketing Intensity (%) - Company Level or Segment Level, 2015-2016
  • Figure 74: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region (overall company), 2016
  • Figure 75: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Business Segment, 2016
  • Figure 76: Mylan, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 77: Mylan, Inc. R&D Intensity and Sales and Marketing Intensity (%) - Company Level or Segment Level, 2015-2016
  • Figure 78: Mylan, Inc. Breakdown of Net Sales, by Region (overall company), 2016
  • Figure 79: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 80: GlaxoSmithKline plc R&D Intensity (%), 2015-2016
  • Figure 81: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2016
  • Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Segment, 2016
  • Figure 83: Daiichi Sankyo Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 84: Daiichi Sankyo Company R&D Intensity (%), 2015-2016
  • Figure 85: Daiichi Sankyo Company Breakdown of Net Sales, by Region, 2016
  • Figure 86: Natco Pharma Net Sales Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 87: Natco Pharma R&D Intensity (%), 2015-2016
  • Figure 88: Natco Pharma Breakdown of Net Sales, by Segment 2017
Back to Top